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Abstract:  
Pharmacogenetics research has advanced our knowledge of the genetic basis of 
individual drug responses. Further benefits stem from the translation of pharmacogenetics 
research into the clinic to identify patients who are at high risk of adverse drug events. However, 
American Indian and Alaska Native (AI/AN) populations have not benefited markedly from 
genetics-guided therapeutics. A key strategy in engaging AI/AN people in pharmacogenetics 
research has been the implementation of a community-based participatory research (CBPR) 
approach, a qualitative research methodology in which a partnership is formed between the 
research institution and the community participating in the research. The main hypothesis is: 
CBPR methods provide a robust basis for addressing knowledge gaps related to 
pharmacogenetics in AI/AN communities. Research has demonstrated multiple positive 
outcomes of utilizing a CBPR approach in AI/AN populations. CBPR provides a framework for 
both partners to be involved in all aspects of the research process, from developing research 
questions to data analysis, and dissemination of research results. Early in the project, approval 
was given by the Confederated Salish and Kootenai Tribes (CSKT) through discussions with 
Tribal Health and Tribal Council to conduct pharmacogenetics research with the CSKT 
community. Thereafter, a collaborative university-community partnership was established with 
the CSKT to develop culturally relevant research strategies. Research goals from this 
partnership include (1) identify resources available in the area of pharmacogenomics research 
to facilitate community involvement and education, (2) assessment of whether pharmacogenetic 
testing would be feasible in CSKT Tribal Health, and (3) identification of views and perceptions 
regarding pharmacogenetics research in the CSKT community. We formed an oversight 
committee, the Community Pharmacogenetics Advisory Council (CPAC), to ensure community 
involvement. We also held workshops to provide education and bring awareness to the 
community about pharmacogenetics research. CPAC members were administered surveys to 
inform us about the value of the workshops and if the workshops were useful as an educational 
tool. Furthermore, using Likert-scale and open-ended questions, the survey assessed the 
degree of knowledge CPAC members felt they had in the area of pharmacogenetics and 
whether participation in the CPAC has improved their knowledge. Likert scales were designed 
on a scale of 1 to 5, with 1 reflecting “considerable knowledge” of pharmacogenetics and 5 
reflecting “no knowledge” of pharmacogenetics. Seventeen healthcare provider interviews were 
conducted with providers in Missoula, Polson, and St. Ignatius, MT to assess their views on the 
potential benefits and harms of pharmacogenetics research and the feasibility of its future 
implementation into Tribal Health. The interviews were transcribed and analyzed using 
Dedoose, an online qualitative software package to identify emerging themes from the 
interviews. In addition, we are conducting focus groups with CSKT members and descendants 
who receive their healthcare through Tribal Health to facilitate discussion around the topic of (1) 
pharmacogenetics research with AI/AN communities, (2) its translation into Tribal Health clinics, 
and (3) dissemination of results to community. Five participants have been recruited thus far (of 
a target 32). CPAC members helped design a moderator’s guide and developed recruitment 
tools for focus groups. Results from the CPAC survey showed that the average score of CPAC 
members knowledge prior to joining the CPAC was 4.5, suggesting they had little to no 
knowledge of pharmacogenetics research. The average score after joining the CPAC was 2.75, 
suggesting that CPAC members felt their knowledge of pharmacogenetics had improved. Not 
 
 
 
only did the average score improve, but every individual member of the CPAC reported an 
increase in knowledge prior to and after joining CPAC. Results from the healthcare provider 
interviews found that participants were optimistic about future potential of pharmacogenetic 
tests, but voiced that such testing may have reduced acceptability, utility, and feasibility in 
rural/tribal practice settings. Participants in tribal community settings identified the heightened 
importance of genetics and the need for community leadership approval as additional 
considerations. Preliminary findings from the focus groups found that CSKT views were overall 
enthusiastic about the potential benefits of pharmacogenetics. However, participants mentioned 
that cultural barriers exist amongst the broader CSKT community, but discussions and 
education efforts could help overcome these barriers. This collaboration between UM, Tribal 
Health, and CSKT community created a CBPR framework that best fits the needs of the 
community. Engaging CSKT community partners in informal and formal discussions about 
pharmacogenetics research has aided in identifying priorities of the community and building 
mutually productive partnerships. Furthermore, this research will significantly expand 
researchers’ and community partners’ capacity that can bring about enduring change, both in 
how pharmacogenetic research is conducted and in it application to improving the health 
disparities of CSKT people. 
